Pemetrexed: A novel antifolate agent enters clinical practice

Victoria Kut, Jyoti D. Patel, Athanassios Argiris

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Pemetrexed (Alimta®, Eli Lilly) is a multitargeted antifolate that inhibits at least three enzymes in the nucleic acid synthetic pathways. The US Food and Drug Administration recently approved pemetrexed, in combination with cisplatin, for the first-line treatment of advanced malignant pleural mesothelioma. Moreover, pemetrexed was recently shown to be as efficacious as docetaxel (Taxotere®, Aventis in the second-line treatment of non-small cell lung cancer, and its toxicity profile was preferable. The main toxicity seen with pemetrexed is myelosuppression, which is considerably reduced by coadministration of folic acid and vitamin B12. Multiple Phase II clinical trials have demonstrated that pemetrexed has promising single-agent activity in many other solid tumors, including head and neck, breast and colorectal cancers. Combination regimens consisting of pemetrexed and other chemotherapeutics or novel molecular-targeted agents are currently under investigation. Future studies will better define and likely expand the role of pemetrexed for the treatment of cancer.

Original languageEnglish (US)
Pages (from-to)511-522
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume4
Issue number4
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Pemetrexed
Folic Acid Antagonists
docetaxel
Phase II Clinical Trials
United States Food and Drug Administration
Vitamin B 12
Head and Neck Neoplasms
Folic Acid
Non-Small Cell Lung Carcinoma
Nucleic Acids
Cisplatin
Colorectal Neoplasms
Neoplasms

Keywords

  • Antifolate
  • Mesothelioma
  • Non-small cell lung cancer
  • Pemetrexed
  • Solid tumors

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Kut, V., Patel, J. D., & Argiris, A. (2004). Pemetrexed: A novel antifolate agent enters clinical practice. Expert Review of Anticancer Therapy, 4(4), 511-522.

Pemetrexed : A novel antifolate agent enters clinical practice. / Kut, Victoria; Patel, Jyoti D.; Argiris, Athanassios.

In: Expert Review of Anticancer Therapy, Vol. 4, No. 4, 08.2004, p. 511-522.

Research output: Contribution to journalArticle

Kut, V, Patel, JD & Argiris, A 2004, 'Pemetrexed: A novel antifolate agent enters clinical practice', Expert Review of Anticancer Therapy, vol. 4, no. 4, pp. 511-522.
Kut, Victoria ; Patel, Jyoti D. ; Argiris, Athanassios. / Pemetrexed : A novel antifolate agent enters clinical practice. In: Expert Review of Anticancer Therapy. 2004 ; Vol. 4, No. 4. pp. 511-522.
@article{30831c186038479891a976e11b17e547,
title = "Pemetrexed: A novel antifolate agent enters clinical practice",
abstract = "Pemetrexed (Alimta{\circledR}, Eli Lilly) is a multitargeted antifolate that inhibits at least three enzymes in the nucleic acid synthetic pathways. The US Food and Drug Administration recently approved pemetrexed, in combination with cisplatin, for the first-line treatment of advanced malignant pleural mesothelioma. Moreover, pemetrexed was recently shown to be as efficacious as docetaxel (Taxotere{\circledR}, Aventis in the second-line treatment of non-small cell lung cancer, and its toxicity profile was preferable. The main toxicity seen with pemetrexed is myelosuppression, which is considerably reduced by coadministration of folic acid and vitamin B12. Multiple Phase II clinical trials have demonstrated that pemetrexed has promising single-agent activity in many other solid tumors, including head and neck, breast and colorectal cancers. Combination regimens consisting of pemetrexed and other chemotherapeutics or novel molecular-targeted agents are currently under investigation. Future studies will better define and likely expand the role of pemetrexed for the treatment of cancer.",
keywords = "Antifolate, Mesothelioma, Non-small cell lung cancer, Pemetrexed, Solid tumors",
author = "Victoria Kut and Patel, {Jyoti D.} and Athanassios Argiris",
year = "2004",
month = "8",
language = "English (US)",
volume = "4",
pages = "511--522",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Pemetrexed

T2 - A novel antifolate agent enters clinical practice

AU - Kut, Victoria

AU - Patel, Jyoti D.

AU - Argiris, Athanassios

PY - 2004/8

Y1 - 2004/8

N2 - Pemetrexed (Alimta®, Eli Lilly) is a multitargeted antifolate that inhibits at least three enzymes in the nucleic acid synthetic pathways. The US Food and Drug Administration recently approved pemetrexed, in combination with cisplatin, for the first-line treatment of advanced malignant pleural mesothelioma. Moreover, pemetrexed was recently shown to be as efficacious as docetaxel (Taxotere®, Aventis in the second-line treatment of non-small cell lung cancer, and its toxicity profile was preferable. The main toxicity seen with pemetrexed is myelosuppression, which is considerably reduced by coadministration of folic acid and vitamin B12. Multiple Phase II clinical trials have demonstrated that pemetrexed has promising single-agent activity in many other solid tumors, including head and neck, breast and colorectal cancers. Combination regimens consisting of pemetrexed and other chemotherapeutics or novel molecular-targeted agents are currently under investigation. Future studies will better define and likely expand the role of pemetrexed for the treatment of cancer.

AB - Pemetrexed (Alimta®, Eli Lilly) is a multitargeted antifolate that inhibits at least three enzymes in the nucleic acid synthetic pathways. The US Food and Drug Administration recently approved pemetrexed, in combination with cisplatin, for the first-line treatment of advanced malignant pleural mesothelioma. Moreover, pemetrexed was recently shown to be as efficacious as docetaxel (Taxotere®, Aventis in the second-line treatment of non-small cell lung cancer, and its toxicity profile was preferable. The main toxicity seen with pemetrexed is myelosuppression, which is considerably reduced by coadministration of folic acid and vitamin B12. Multiple Phase II clinical trials have demonstrated that pemetrexed has promising single-agent activity in many other solid tumors, including head and neck, breast and colorectal cancers. Combination regimens consisting of pemetrexed and other chemotherapeutics or novel molecular-targeted agents are currently under investigation. Future studies will better define and likely expand the role of pemetrexed for the treatment of cancer.

KW - Antifolate

KW - Mesothelioma

KW - Non-small cell lung cancer

KW - Pemetrexed

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=4444351115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444351115&partnerID=8YFLogxK

M3 - Article

C2 - 15270656

AN - SCOPUS:4444351115

VL - 4

SP - 511

EP - 522

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 4

ER -